Indoco Remedies has reported its financial results for the first quarter of FY 2026–27, with revenue increasing to INR 4,081 million from INR 3,856 million in the corresponding quarter of the previous financial year.

The company's EBITDA stood at INR 422 million, with an EBITDA margin of 10.3 percent, compared with INR 148 million and an EBITDA margin of 3.8 percent in the same quarter last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies, said, "The first quarter of the financial year 2026–27 reflects the continued execution of our long-term strategy focused on deliverables from our core businesses despite a dynamic operating environment. The growth in this quarter is due to the resilient domestic formulation business, while our international formulations and API businesses continued to make steady progress."

Indoco Remedies operates 10 manufacturing facilities, including six finished dosage formulation (FDF) plants and four API manufacturing facilities, supported by a state-of-the-art R&D centre and a CRO facility.